Robotic partial nephrectomy appears to be a reasonable option for certain renal masses, provided that an experienced surgeon performs the procedure at a center that can manage postoperative complications, researchers concluded after conducting an analysis involving nearly 1,800 individuals. Participants had cT1a (n=1358), cT1b (n=379), or cT2a (n=41) renal masses. Investigators looked at how intra and postoperative outcomes in patients with cT2a masses compared to those with the other 2 mass types. Among the results:
- Performing robotic surgery on cT2a vs cT1a masses resulted in a 12% longer operative time, 32% increase in estimated blood loss, 7% increase in ischemia time, nearly 4-fold higher odds of acute kidney injury at discharge, and a nearly 11-fold higher recurrence risk.
- Performing the procedure on cT2a vs cT1b masses resulted in a 12% increase in blood loss.
- Operative time and recurrence risk were not statistically different.
- Complications, positive margins, length of stay, and renal function decline up to 2 years post-procedure were not statistically different.
Delto J, Paulucci D, Helbig M, et al. Robotic partial nephrectomy for large renal masses: A multi-institutional series. [Published online ahead of print January 22, 2018]. BJU Int. doi:10.1111/bju.14139.
This Week's Must Reads
Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885
Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291
Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04
Outcomes better in TNBC with adjuvant chemotherapy within 30 days of surgery, Morante Z et al., SABCS 2018 Abstract GS2-05
Must Reads in Renal Cell Carcinoma
One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617
Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4
Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010
RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021
Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001